Reply to Scagnolari et al

Affiliations

¹ Institute for Therapeutic Innovation, Department of Medicine, University of Florida, Orlando.
² Department of Biomedical Engineering, University of Southern California, Los Angeles.

Comment

Ashley N Brown et al. J Infect Dis. 2017.

. 2017 Feb 1;215(3):493-494.

doi: 10.1093/infdis/jiw580.

¹ Institute for Therapeutic Innovation, Department of Medicine, University of Florida, Orlando.
² Department of Biomedical Engineering, University of Southern California, Los Angeles.

No abstract available

Comment on

Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
Gallegos KM, Drusano GL, D Argenio DZ, Brown AN. Gallegos KM, et al. J Infect Dis. 2016 Oct 15;214(8):1192-7. doi: 10.1093/infdis/jiw358. Epub 2016 Aug 5. J Infect Dis. 2016. PMID: 27496974 Free PMC article.
Antiviral Activity of the Combination of Interferon and Ribavirin Against Chikungunya Virus: Are the Results Conclusive?
Scagnolari C, Caputo B, Rezza G, Antonelli G. Scagnolari C, et al. J Infect Dis. 2017 Feb 1;215(3):492-493. doi: 10.1093/infdis/jiw579. J Infect Dis. 2017. PMID: 28003356 No abstract available.